MEDVi vs Remedy Meds vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you’re cross-shopping MEDVi and Remedy Meds for cash-pay GLP-1 weight loss, both pages look almost identical: similar brand voice, similar starting prices, similar “all-inclusive” promises. The difference is in the fine print — what each provider charges at refill, how the billing cycle is timed, what pharmacy actually fills the prescription, and what the September 2025 FDA warning letter to compounded-GLP-1 marketers means for both. This guide walks the actual annual cost on each side, the compounded vs FDA-approved branded distinction, the safety considerations all three platforms share, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and the Microdose GLP-1 Protocol sit relative to MEDVi and Remedy Meds — because the choice between three compounded-GLP-1 platforms isn’t really about which company is “better.” It’s about total annualized cost, billing cadence, oversight model, and whether your dose is anchored to a genetic baseline or to a population-average titration schedule.

MEDVi vs Remedy Meds vs PlexusDx — quick decision frame

Three cash-pay compounded-GLP-1 platforms, three pricing models. MEDVi uses promotional first-month pricing that steps up at refill: $179 first month for compounded semaglutide then $299/month at refill, and $349 first month for compounded tirzepatide then $249-$369/mo at refill depending on dose. Remedy Meds charges flat dose-agnostic pricing: $299/month for compounded semaglutide and $399/month for compounded tirzepatide at every dose level — billed every 28 days, which adds roughly one extra payment per year compared with monthly billing. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, the Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared dual-compound therapy at $249/mo — with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing decisions are anchored to GLP1R, FTO, MC4R, and TCF7L2 variants rather than starting from population averages. All three platforms are cash-pay; PlexusDx adds no membership fee, runs in all 50 states, and bills monthly — not every 28 days.

The real annual cost: MEDVi vs Remedy Meds vs PlexusDx

For a cash-pay patient with no GLP-1 coverage, MEDVi’s semaglutide path totals roughly $3,468/year ($179 month one + $299 × 11) and the tirzepatide path runs ~$4,738–$5,838/year depending on the refill tier ($349 month one + $249-$369/mo × 11). Remedy Meds’s 28-day billing cycle produces about 13 charges per calendar year — ~$3,887/year for compounded semaglutide ($299 × 13) and ~$5,187/year for compounded tirzepatide ($399 × 13). PlexusDx Weight Management Protocols range from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), or $2,148–$3,900/year on GLP-Squared dual-compound ($249/mo). Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay below MEDVi’s tirzepatide refill tier and below Remedy Meds’s 13-cycle annual total on both molecules at the entry and mid-tier dose levels.

Compounded vs FDA-approved branded — what each platform actually dispenses

All three platforms in this comparison dispense compounded semaglutide and tirzepatide — formulations prepared by licensed U.S. compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. The FDA has noted that compounded versions may contain different salt forms than the FDA-approved finished products, which is part of the regulatory distinction. None of the three platforms can accurately call their compounded product “FDA-approved” — only the branded finished drugs (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, Trulicity, Victoza) hold that status. MEDVi separately offers brand-name Ozempic at retail-tier pricing, which is FDA-approved as a finished product. Remedy Meds dispenses compounded only. PlexusDx dispenses compounded only and adds delivery-format optionality — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks — that neither MEDVi nor Remedy Meds matches.

The September 2025 FDA warning-letter context

On September 9, 2025, the FDA issued warning letters to multiple compounded-GLP-1 telehealth marketers — including Remedy Meds and Hims & Hers — about marketing language the agency considered false or misleading, specifically regarding equating compounded products with FDA-approved drugs. The warning letters did not allege a product-safety failure; they addressed claims and comparative language. The takeaway for any patient evaluating compounded-GLP-1 telehealth is the same regardless of platform: a compounded product is not the FDA-approved finished drug, the platform is not “FDA-approved,” and any provider that conflates the two is making a marketing claim the FDA has already taken enforcement action against. PlexusDx Weight Management Protocols describe compounded semaglutide and tirzepatide as compounded — not FDA-approved — in product-page disclosures, and the Precision Peptide Genetic Test is positioned as a clinical-decision aid rather than a regulatory substitute.

Safety, side effects, and clinical oversight

All three platforms prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The labeled side-effect profile is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented; the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies and applies to compounded versions of both molecules as well. Clinical oversight differs at the margins. Remedy Meds advertises unlimited scheduled video calls and operates in all 50 states plus DC. MEDVi advertises clinician access on request and operates in select states — confirm during eligibility check. PlexusDx operates in all 50 states (five require a scheduled live consultation rather than async intake), uses licensed U.S. compounding pharmacies, and reviews the patient’s genetic test before titration when the test is included — a stratification step neither MEDVi nor Remedy Meds performs. Cold-chain shipping is standard at all three; if any GLP-1 medication arrives warm, do not use it — contact your provider.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician knows whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither MEDVi nor Remedy Meds performs this step; both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol. For a patient who has tried a GLP-1 before and didn’t respond as expected, this is the single biggest difference between the three platforms.

Cancellation, refunds, and billing-cycle reality

MEDVi requires cancellation at least 72 hours before the next billing date and will only refund a cycle if medication hasn’t already been ordered for that cycle. Remedy Meds requires cancellation at least 48 hours before renewal through the portal; charges become non-refundable once payment processes. Remedy Meds’s 28-day billing cycle is the easiest cost item to miss — it means about 13 charges per calendar year rather than 12, adding roughly one extra payment annually ($299 for semaglutide or $399 for tirzepatide). PlexusDx Weight Management Protocols bill monthly with no membership fee — cancellation is processed through the patient portal and a cycle is refundable per the protocol terms before medication is dispensed. Across all three platforms, you cannot “transfer” a compounded prescription between providers — if you switch, the new provider performs their own intake.

Which one fits — a four-question frame

Question 1: Are you comparing first-month price only, or annualized total? If first-month, MEDVi’s $179 semaglutide intro is the lowest of the three. If annualized, PlexusDx Microdose GLP-1 Protocol at $1,548/year and Semaglutide Injection at $2,148–$2,748/year are below both MEDVi’s ~$3,468/year refill total and Remedy Meds’s ~$3,887/year 13-cycle total. Question 2: Do you value flat dose-agnostic pricing? Remedy Meds is the only one of the three with that structure. Question 3: Do you want a delivery format other than weekly injection? PlexusDx offers oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks — MEDVi offers oral and injection; Remedy Meds is injection only. Question 4: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only platform in this comparison that includes the Precision Peptide Genetic Test in the protocol pathway.

Frequently asked questions

Which is cheaper long-term: MEDVi, Remedy Meds, or PlexusDx?

On annualized cost for a cash-pay patient, PlexusDx is cheapest at the entry tier. The Microdose GLP-1 Protocol runs $1,548/year and Semaglutide Injection runs $2,148–$2,748/year — below MEDVi’s ~$3,468/year semaglutide total and Remedy Meds’s ~$3,887/year 13-cycle semaglutide total.

Are MEDVi, Remedy Meds, or PlexusDx FDA-approved?

None of the compounded products dispensed by these three platforms are FDA-approved as finished drugs. Compounded semaglutide and tirzepatide are prepared by licensed U.S. compounding pharmacies and fall under compounding regulations, not the FDA new-drug approval pathway. Only branded finished products like Wegovy, Ozempic, Zepbound, and Mounjaro hold FDA approval.

Did the FDA warn Remedy Meds in 2025?

Yes. On September 9, 2025, the FDA issued a warning letter to Remedy Meds and several other compounded-GLP-1 telehealth marketers about marketing language the agency considered false or misleading. The letter addressed claims and comparative wording, not a product-safety failure.

Does Remedy Meds really bill every 28 days instead of monthly?

Yes. Remedy Meds’s 28-day cycle produces about 13 charges per calendar year. For semaglutide that is approximately $3,887/year ($299 × 13); for tirzepatide approximately $5,187/year ($399 × 13). PlexusDx bills monthly with no membership fee.

Why is PlexusDx cheaper than MEDVi or Remedy Meds at the entry tier?

PlexusDx Weight Management Protocols are cash-pay, all-inclusive, with no membership fee — the Microdose GLP-1 Protocol at $129/mo flat and Semaglutide Injection from $179/mo cover the async clinician consult, compounded medication, and shipping in one bill, with no first-month-promo step-up at refill.

Should I get the genetic test before starting a GLP-1?

If you have tried a GLP-1 before and did not respond as expected, or if you want to know whether a faster or slower titration is more likely to fit your biology, the Precision Peptide Genetic Test is worth considering — $298 standalone or $99 as an add-on after your first month on any PlexusDx protocol. Neither MEDVi nor Remedy Meds offers this stratification step.

Can I switch from one platform to another later?

Yes. None of the three lock patients into long-term contracts. Cancel through the platform’s stated procedure (72 hours before billing for MEDVi, 48 hours before renewal for Remedy Meds, monthly cycle terms for PlexusDx) and start fresh with the other provider. You cannot transfer a compounded prescription — the new platform performs its own intake.

MEDVi vs Remedy Meds vs PlexusDx (2026): Compounded GLP-1 Cost & FDA Facts | PlexusDx